We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$10.2B
AUM Growth
-$819M
Cap. Flow
-$1.84B
Cap. Flow %
-18.03%
Top 10 Hldgs %
83.92%
Holding
140
New
7
Increased
13
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$96.9M
2
ONC
BeOne Medicines Ltd
ONC
+$55.3M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$38.3M
4
AKAO
Achaogen Inc
AKAO
+$30.7M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$773M
2
EXEL icon
Exelixis
EXEL
+$27.8M
3
TGTX icon
TG Therapeutics
TGTX
+$15.5M
4
ARWR icon
Arrowhead Research
ARWR
+$13.6M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.85%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
26
DELISTED
Merus
MRUS
$24.5M 0.24%
1,160,014
– –
XNCR icon
27
Xencor
XNCR
$2.07B
$23M 0.23%
872,072
– –
ARRY
28
DELISTED
Array Biopharma Inc
ARRY
$22.7M 0.22%
2,585,913
-724,753
-22% -$5.33M
BLUE
29
DELISTED
bluebird bio
BLUE
$21.7M 0.21%
27,131
+4,439
+20% +$3.52M
ASND icon
30
Ascendis Pharma A/S
ASND
$16.6B
$20.7M 0.2%
1,023,266
+277,745
+37% +$5.55M
DSCI
31
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$19.5M 0.19%
3,752,390
– –
LKFT
32
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$16.7M 0.16%
259,894
– –
ACGN
33
DELISTED
Aceragen Inc
ACGN
$15.4M 0.15%
75,607
+23,982
+46% +$5.72M
AVXS
34
DELISTED
AveXis, Inc. Common Stock
AVXS
$15M 0.15%
+315,300
New +$16.8M
NTLA icon
35
Intellia Therapeutics
NTLA
$1.8B
$13.9M 0.14%
1,062,120
– –
AIMT
36
DELISTED
Aimmune Therapeutics
AIMT
$13.8M 0.14%
673,908
– –
HALO icon
37
Halozyme
HALO
$12.3B
$13.7M 0.13%
1,391,507
-339,550
-20% -$3.72M
NDRM
38
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$12.7M 0.12%
571,667
+266,667
+87% +$4.99M
SGMO
39
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$12.4M 0.12%
4,055,876
– –
AERI
40
DELISTED
Aerie Pharmaceuticals
AERI
$11.3M 0.11%
299,356
– –
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$10.8M 0.11%
2,269,198
– –
SAGE
42
DELISTED
Sage Therapeutics
SAGE
$10.6M 0.1%
208,328
– –
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
$10.2M 0.1%
838,809
-161,191
-16% -$1.77M
DERM
44
DELISTED
Dermira, Inc.
DERM
$9.9M 0.1%
326,428
– –
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.19M 0.09%
609,166
– –
ALKS icon
46
Alkermes
ALKS
$8.11B
$8.35M 0.08%
150,251
-100,000
-40% -$5.35M
ABEO icon
47
Abeona Therapeutics
ABEO
$348M
$8.17M 0.08%
67,375
+63,308
+1,557% +$9.91M
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
$7.67M 0.08%
1,856,637
-618,878
-25% -$3.29M
LGND icon
49
Ligand Pharmaceuticals
LGND
$5.71B
$7.46M 0.07%
117,638
– –
MGNX icon
50
MacroGenics
MGNX
$261M
$7.43M 0.07%
363,676
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2016 Portfolio in Review

As of Q4 2016, Julian Baker held 140 positions worth $10.2B, down 7.4% from $11B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Julian Baker withdrew a net $1.84B in Q4 2016, closing 7 positions and reducing 18 holdings. Its most notable exit was TG Therapeutics, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 88% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in AveXis, Inc. Common Stock worth $15M.

  • Julian Baker's largest Q4 2016 buy was AveXis, Inc. Common Stock: 315,300 shares worth $15M.
  • Julian Baker added most to Seagen Inc. Common Stock in Q4 2016, an estimated $96.9M increase.
  • Julian Baker's biggest Q4 2016 reduction was AbbVie, cutting an estimated $773M.
  • Julian Baker fully exited TG Therapeutics in Q4 2016, selling an estimated $15.5M.
  • Julian Baker's ten largest holdings make up 84% of its $10.2B portfolio in Q4 2016.
  • Julian Baker opened 7 new positions and closed 7 in Q4 2016.
  • Julian Baker's portfolio value fell 7.4% quarter-over-quarter to $10.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.